AUA 2024 Prostate Cancer - Results from #40

Viewing 41-60 of 65 articles

AUA 2024: Correlation of Intraprostatic SUVmax During PSMA PET/CT and Adverse Pathology at Radical Prostatectomy

AUA 2024: Clinical Characterization of Metastatic Hormone Sensitive Prostate Cancer According to Real World Data: Can Randomized Clinical Trials Be More Reliable? Data from the European Network of Excellence for Big Data in Prostate Cancer (PIONEER)

AUA 2024: The Added Value of Concomitant Whole-Pelvis Salvage Radiation Therapy in Oligo-Recurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy for Distant Positive Uptakes at PSMA PET

AUA 2024: Development of a Prediction Model of Survival Amongst Patients with Metastatic Hormone Sensitive Prostate Cancer Using Big Data: Interim Results from the European Network of Excellence for Big Data in Prostate Cancer (PIONEER)

AUA 2024: The Role of PSA Doubling Time in the Stratification of Patients with a Negative PSMA PET After Biochemical Recurrence of Prostate Cancer: Implications for Tailored Salvage Treatment Strategies

AUA 2024: Evaluating the Role of Telemedicine in Reducing Racial and Ethnic Disparities in Prostate Cancer Care

AUA 2024: Descriptive Tumor Characteristics of 992 Consecutive Patients Who Underwent Staging with PSMA PET/CT Before Radical Prostatectomy.

AUA 2024: Greening the Operating Room (GOR): High-Impact Initiatives Urologists’ Can Facilitate to Jumpstart a Program

AUA 2024: ARV-766, a PROTAC Androgen Receptor Degrader, Combined with Abiraterone in Novel Hormonal Agent (NHA)-Naïve Metastatic Prostate Cancer: Phase 1 Cohort (Part C) of a Phase 1/2 Study

AUA 2024: Determinants of Financial Toxicity in Patients with Urologic Cancer

AUA 2024: Impact of 18F-DCFPyL on Accuracy of mpMRI in Men with Low and Intermediate Risk Prostate Cancer: Interim Analysis of a Phase II Diagnostic Trial

AUA 2024: The Impact of Delayed Administration of Androgen-Receptor Signaling Inhibitors (ARSI) on Prognosis for mHSPC

AUA 2024: Paradigm-Shifting, Practice-Changing Clinical Trials in Urology: PSMAfore: Efficacy of 177Lu-PSMA-617 Versus ARPI Change in Taxane-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer by Pre-Randomization ARPI

AUA 2024: Paradigm-Shifting, Practice-Changing Clinical Trials in Urology: Apalutamide and ADT for the Treatment of High-Risk Localized Prostate Cancer Following Radical Prostatectomy in Apa-RP: A Multicenter, Open-Label, Single Arm Trial

AUA 2024: PSMA PET/CT-Detected Mesorectal Nodal Metastasis in Biochemically Recurrent Prostate Cancer Patients

AUA 2024: Paradigm-Shifting, Practice-Changing Clinical Trials in Urology: The Next Generation Trial: Assessing 18F-PSMA-1007 PET and MRI in Primary Staging of Prostate Cancer Patients

AUA 2024: Rates and Predictors of False Node-Positive PSMA-PET in Patients Treated with Radical Prostatectomy and Extend Pelvic Lymph-Node Dissection: Results From a Large, Multi-Institutional Database

AUA 2024: AUA Guidelines: Salvage Therapy for Prostate Cancer

AUA 2024: Third Interim Analysis of the DARolutamide ObservationaL (DAROL) Study in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

AUA 2024: Phase I Dose-Escalation Trial of Multiple and Fractionated-Dose PSMA-Targeted Alpha Radionuclide (225Ac-J591) for Metastatic Castration-Resistant Prostate Cancer

1
2
3
4